Overview
Mermaid diagram (expand to render)
SanBio Co., Ltd. (サンバイオ株式会社) is a Japanese regenerative medicine company headquartered in Tokyo, Japan, with a primary focus on developing cell therapy medicines for the treatment of neurological disorders and injuries. The company is listed on the Tokyo Stock Exchange (TSE: 4592) and has established itself as a leader in the field of cellular therapeutics for central nervous system (CNS) conditions["@sanbio"].
SanBio's proprietary cell therapy platform is based on allogeneic (donor-derived) mesenchymal stromal cells (MSCs) that are processed using the company's proprietary methodology to enhance their therapeutic potential. The lead product candidate, SB623, has been evaluated in multiple clinical trials for the treatment of neurological deficits resulting from traumatic brain injury (TBI) and ischemic stroke["@sb623tbi"][@sb623stroke].
The company's mission centers on developing innovative regenerative medicine therapies that restore neurological function and improve quality of life for patients with conditions that currently have limited treatment options. SanBio's approach leverages the natural regenerative capabilities of the human body by harnessing the therapeutic potential of specially processed stem cells["@sanbioa"].
Company Background
Corporate History
SanBio was established in 1999 with a vision to advance regenerative medicine approaches for the treatment of neurological disorders. The company was founded based on research conducted by Professor Hideyuki Okano, a leading figure in regenerative medicine and stem cell biology at Keio University in Tokyo[@sanbio].
Key Milestones:
| Year | Event |
|------|-------|
| 1999 | Company founded in Tokyo |
| 2001 | Initiation of SB623 research program |
| 2005 | Preclinical development begins |
| 2011 | First-in-human clinical trial initiated |
| 2014 | Phase 1/2a trial for TBI initiated |
| 2016 | Phase 2 trial for stroke initiated |
| 2019 | Phase 2 results announced |
| 2021 | Japanese regulatory consultation |
| 2025 | AKUUGO approval for TBI |
Organizational Structure
Corporate Overview:
- Headquarters: Tokyo, Japan
- Stock Exchange: Tokyo Stock Exchange (TSE: 4592)
- Employees: Approximately 200-300
- CEO: Keita Mori
- Founded: 1999
Leadership:
- Keita Mori: President & CEO - Leads corporate strategy and operations
- Professor Hideyuki Okano: Founding Scientific Advisor - Pioneer in iPSC and regenerative medicine research
- Shinya Hirata: Head of R&D - Oversees research and development programs
- Keizo Nakada: Head of Production - Manages manufacturing and quality
- Dr. Damien Bates: Chief Medical Officer - Leads clinical development and medical affairs
Board Structure:
- Board of Directors with independent outside directors
- Audit and Supervisory Committee
- Scientific Advisory Board
Business Model
SanBio operates as a specialty regenerative medicine company focused on:
- Development of cell therapy products for neurological conditions
- Manufacturing of cellular products under GMP conditions
- Clinical development through regulatory approval
- Commercialization in Japan and potential international markets
Mesenchymal Stromal Cell (MSC) Technology
SanBio's technology platform is based on allogeneic mesenchymal stromal cells derived from healthy donor bone marrow. These cells undergo proprietary processing to enhance their therapeutic properties and are administered directly to the affected region of the brain[@msc][@regenerative].
MSC Biology:
Mesenchymal stromal cells are multipotent stem cells that can differentiate into various connective tissue cell types. However, their therapeutic potential in neurological applications is primarily mediated through paracrine signaling rather than direct cell replacement.
Key Properties:
Immunomodulatory Capacity: MSCs can modulate immune responses and reduce inflammation
Paracrine Secretion: Produce neurotrophic factors that support neural cell survival
Migration: Can migrate to sites of injury and inflammation
Safety Profile: Established safety in multiple clinical applicationsSB623: Lead Product Candidate
SB623 is SanBio's lead product candidate—a population of allogeneic bone marrow-derived mesenchymal stromal cells that are processed using the company's proprietary methodology[@product].
Product Characteristics:
| Property | Description |
|----------|-------------|
| Cell Source | Human bone marrow (allogeneic) |
| Processing | Proprietary methodology |
| Administration | Intracranial implantation |
| Indication | Neurological deficits from TBI/stroke |
| Stage | Clinical development |
Mechanism of Action:
SB623 exerts its therapeutic effects through multiple mechanisms:
Neurotrophic Factor Secretion: The cells secrete growth factors including:
- Brain-derived neurotrophic factor (BDNF)
- Glial cell line-derived neurotrophic factor (GDNF)
- Nerve growth factor (NGF)
- Vascular endothelial growth factor (VEGF)[@bdnf][@gdntf]
Immunomodulation: MSCs modulate the immune response:
- Reduce pro-inflammatory cytokines
- Increase anti-inflammatory factors
- Promote regulatory T-cell function[@inflammation]
Endogenous Repair Activation: Stimulate endogenous repair mechanisms:
- Promote angiogenesis
- Support neural progenitor cell function
- Enhance synaptic plasticity
Neuronal Protection: Protect existing neurons from death:
- Anti-apoptotic effects
- Antioxidant properties
- Support mitochondrial function
Proprietary Processing
SanBio's proprietary processing method differentiates SB623 from other MSC-based approaches:
Processing Steps:
Bone marrow collection from healthy donors
MSC isolation and expansion
Proprietary activation treatment
Quality control and characterization
Formulation for implantationKey Advantages:
- Enhanced neurotrophic factor secretion
- Improved survival after implantation
- Consistent product quality
- Scalable manufacturing
Clinical Development Program
Traumatic Brain Injury (TBI)
Phase 1/2a Study
SanBio conducted a Phase 1/2a clinical trial evaluating SB623 in patients with chronic neurological deficits following traumatic brain injury[@sb623tbi].
Study Design:
- Design: Open-label, dose-escalation
- Patients: Adults with chronic motor deficits from TBI (≥12 months post-injury)
- Dose: Multiple dose cohorts
- Administration: Single intracranial implantation
Primary Endpoints:
- Safety and tolerability
- Neurological function assessment
Results:The trial demonstrated:
- Acceptable safety profile
- Preliminary evidence of neurological improvement
- Dose-response relationship observed
Phase 2 Study
A larger Phase 2 study further evaluated SB623 in TBI patients[@sb623tbi].
Study Design:
- Design: Randomized, double-blind, placebo-controlled
- Patients: Chronic TBI with motor deficits
- Primary Endpoint: Change in motor function scores
Results:
- Primary endpoint met in modified analysis
- Clinically meaningful improvements observed
- Durable effects at long-term follow-up
Ischemic Stroke
Phase 2 Study
SanBio initiated a Phase 2 clinical trial evaluating SB623 in patients with chronic neurological deficits from ischemic stroke[@sb623stroke].
Study Design:
- Design: Randomized, double-blind, placebo-controlled
- Patients: Adults with chronic stroke (6-60 months post-stroke)
- Primary Endpoint: Motor function improvement
Endpoints:
- Motor recovery measures
- Functional independence
- Quality of life assessments
- Imaging biomarkers
Status:
- Enrollment completed
- Results published
Biomarker Research
SanBio has implemented biomarker research to support clinical development:
Biomarkers Studied:
- Neuroimaging (MRI)
- CSF neurotrophic factors
- Inflammatory markers
- Functional outcome measures
Purpose:
- Patient selection and stratification
- Response prediction
- Mechanism of action validation
- Dose selection
Regulatory Status
Japanese Regulatory Pathway
SanBio is pursuing regulatory approval in Japan through the Pharmaceuticals and Medical Devices Agency (PMDA)[@japanreg].
Regulatory Framework:
Japan has established a dedicated regulatory pathway for regenerative medicine products:
Conditional Approval: For products with provisional conditions
Accelerated Approval: Based on surrogate endpoints
Priority Review: For serious conditions with unmet needsAKUUGO® Approval
In December 2025, SanBio received partial change approval for AKUUGO® (SB623) for the treatment of chronic neurological deficits resulting from traumatic brain injury in Japan[@akuugo2025].
Significance:
- First cell therapy product for TBI in Japan
- Validates SanBio's technology platform
- Enables commercialization in Japanese market
International Regulatory Strategy
SanBio is evaluating regulatory strategies for other markets:
Potential Markets:
- United States (FDA)
- European Union (EMA)
- Other Asian markets
Approach:
- Leverage Japanese approval for international submissions
- Adaptive trial designs for efficiency
- Regulatory pre-submission meetings
Pipeline and Future Programs
Current Pipeline
| Product | Indication | Stage | Status |
|---------|------------|-------|--------|
| SB623 (AKUUGO®) | TBI (chronic) | Approved (Japan) | Launched |
| SB623 | Stroke (chronic) | Phase 2 | Completed |
| Next-generation | Various | Discovery | Preclinical |
Future Development Priorities
Stroke Indication: Pursue regulatory approval for SB623 in stroke
Combination Approaches: Explore combination with rehabilitation
Next-Generation Products: Develop enhanced cell therapy candidates
Additional Indications: Evaluate other neurological conditionsResearch Programs
Preclinical Programs:
- Enhanced cell formulations
- Combination with pharmacological agents
- Alternative delivery methods
Exploratory Research:
- Molecular mechanisms of action
- Biomarker development
- Patient selection criteria
Scientific Approach
Cell Therapy for CNS Disorders
SanBio's approach to treating neurological disorders represents a paradigm shift from traditional pharmacological interventions[@celltherapy][@neuralrepair].
Rationale:
Traditional drug development for CNS disorders faces significant challenges:
- Blood-brain barrier limits drug delivery
- Complex neuronal circuits difficult to target
- Limited regenerative capacity of adult CNS
Cell therapy offers a complementary approach:
- Cells can be administered directly to the brain
- Provide sustained therapeutic signaling
- Activate endogenous repair mechanisms
Advantages of MSC-Based Therapy:| Advantage | Description |
|-----------|-------------|
| Paracrine Signaling | Release multiple therapeutic factors |
| Immunomodulation | Reduce harmful inflammation |
| Safety | Established safety profile |
| Scalability | Manufacturing feasibility |
| Allogeneic Use | Off-the-shelf availability |
Mechanisms of Neural Repair
SB623 promotes neural repair through multiple parallel pathways[@nogo][@neuralrepair]:
1. Neurotrophic Support:
The secreted neurotrophic factors support neuron survival and function:
- BDNF: Supports synaptic plasticity and cognitive function
- GDNF: Protects dopaminergic and motor neurons
- NGF: Supports cholinergic neurons and memory
2. Immunomodulation:MSCs modulate the immune response:
- Reduce microglial activation
- Shift from pro-inflammatory to anti-inflammatory state
- Create environment favorable for repair
3. Regeneration Support:The cells create a permissive environment for regeneration:
- Anti-Nogo effects (promote axon growth)
- Support angiogenesis
- Enhance neural progenitor cell activity
Clinical Experience and Safety
The clinical development program has established a safety profile for SB623:
Safety Findings:
- No serious adverse events related to product
- Intracranial implantation procedures well-tolerated
- No tumor formation observed
- No immune rejection of allogeneic cells
Adverse Events (Non-serious):
- Post-operative pain
- Headache
- Temporary neurological symptoms
Competitive Landscape
Cell Therapy Competition
SanBio occupies a unique position in the cell therapy landscape for CNS disorders:
| Company | Product | Indication | Stage |
|---------|---------|------------|-------|
| SanBio | SB623 | TBI/Stroke | Phase 2/Approved |
| ReNeuron | CTX0E16 | Stroke | Phase 2 |
| Neuralstem | NSI-566 | ALS | Phase 2 |
| Cytokinetics | Various | Spinal cord injury | Preclinical |
Competitive Advantages
SanBio's competitive position includes:
- Proprietary processing technology
- Allogeneic (off-the-shelf) product
- Strong IP portfolio
- Established safety database
- Japanese regulatory success
Stock and Market Data
Exchange Listing:
- Stock Exchange: Tokyo Stock Exchange
- Ticker: 4592
- Listing Date: 2015
Market Capitalization:Approximately $500 million - $1 billion (as of recent reporting)[@tse]
Revenue and Investment:
- R&D investment significant
- No commercial revenue until AKUUGO launch
- Funding through partnerships and equity
Investment in Programs:
- Clinical trial costs
- Manufacturing infrastructure
- Regulatory activities
Relevance to Neurodegeneration
Connections to Neurodegenerative Disease
While SanBio's current focus is on traumatic brain injury and stroke, the technology has significant relevance to neurodegenerative disease research[@regenerative][@celltherapy].
Relevance to Alzheimer's Disease:
- Neurotrophic factor delivery could support cholinergic neurons
- Immunomodulatory effects may reduce neuroinflammation
- Platform technology adaptable to AD
Relevance to Parkinson's Disease:
- GDNF secretion could protect dopaminergic neurons
- Cell therapy approach to motor symptoms
- Potential for disease modification
Relevance to Other Conditions:
- Amyotrophic lateral sclerosis (ALS)
- Spinal cord injury
- Multiple sclerosis
- Huntington's disease
Research Contributions
SanBio's research contributes to the broader field of regenerative medicine:
Mechanistic Understanding: Elucidating how cell therapies promote repair
Clinical Translation: Establishing pathways for cell therapy approval
Manufacturing: Developing scalable production methods
Safety: Characterizing long-term safety of cell therapiesPartnerships and Collaborations
Academic Collaborations
SanBio maintains collaborations with leading Japanese research institutions:
Keio University:
- Founding scientific connection
- Ongoing research collaboration
- Technology access
Other Academic Partners:
- National Center of Neurology and Psychiatry
- University research collaborations
Industry Partnerships
SanBio evaluates partnership opportunities for:
- Co-development arrangements
- Manufacturing partnerships
- Commercialization agreements
- International expansion
Government Relationships
Engagement with Japanese regulatory and funding bodies:
- PMDA regulatory discussions
- Ministry of Health support
- Economic development programs
Manufacturing and Operations
GMP Manufacturing
SanBio operates GMP manufacturing facilities for cellular products:
Manufacturing Capabilities:
- Cell culture and expansion
- Quality control testing
- Product characterization
- Fill and finish
Quality Systems:
- GMP compliance
- Quality management systems
- Regulatory compliance
Supply Chain
Cell Source:
- Healthy donor bone marrow
- Established donor network
- Screening and testing protocols
Production Process:
- Consistent product quality
- Scalable production
- Inventory management
Future Directions
Strategic Vision
SanBio's long-term strategy includes:
Successful Launch: Achieve commercial success with AKUUGO in Japan
Stroke Development: Pursue SB623 approval for stroke indication
Geographic Expansion: Enter international markets
Technology Advancement: Develop next-generation productsGrowth Opportunities
Market Potential:
- Large patient populations with TBI and stroke
- Limited treatment options for chronic deficits
- Growing acceptance of regenerative medicine
Pipeline Expansion:
- Additional neurological indications under evaluation
- Combination therapy approaches with rehabilitation
- Next-generation cell products in development
- Geographic expansion opportunities
Challenges
Development Risks:
- Regulatory pathway in other markets
- Manufacturing scale-up
- Reimbursement challenges
- Competition from other approaches
Operational Considerations:
- Maintaining product quality at scale
- Supply chain management
- Skilled workforce requirements
- Regulatory compliance across jurisdictions
Clinical Development Results
TBI Trial Results Summary
Phase 1/2a Results:
The initial clinical trial demonstrated:
- Favorable safety profile at all dose levels
- Evidence of neurological improvement in treated patients
- Dose-dependent response observed
- Effects maintained at long-term follow-up
Phase 2 Results:
- Primary efficacy endpoint met in modified analysis
- Clinically meaningful improvements in motor function
- Improvements observed across multiple assessment tools
- Benefits sustained through 12-month follow-up
Stroke Trial Results Summary
Phase 2 Results:
- Safety profile confirmed in stroke population
- Signals of efficacy observed in motor recovery
- Subgroup analyses suggest benefit in certain patient populations
- Data support further development in stroke indication
Biomarker Findings
Imaging Biomarkers:
- MRI evidence of structural changes in some patients
- No concerning findings indicative of tumor formation
- Post-treatment changes consistent with repair mechanisms
Fluid Biomarkers:
- Neurotrophic factor levels measurable post-treatment
- Inflammatory marker changes consistent with immunomodulation
- No concerning safety signals in biomarker profiles
Market Access and Reimbursement
Japanese Market
Reimbursement Framework:
- Established pricing methodology for regenerative medicine products
- Consideration of value-based pricing
- Review by relevant Japanese authorities
Market Access Strategy:
- Launch through specialized hospital networks
- Reimbursement discussions with Japanese payors
- Patient access programs
International Markets
US Market Considerations:
- FDA regulatory pathway evaluation
- Pricing and reimbursement strategy development
- Market size and opportunity assessment
EU Market Considerations:
- EMA regulatory engagement
- EU market access strategy
- Pricing and reimbursement across member states
Manufacturing Excellence
Quality Management
SanBio maintains robust quality management systems:
Quality Assurance:
- GMP-compliant manufacturing
- Rigorous quality control testing
- Comprehensive documentation
- Regular audits and inspections
Regulatory Compliance:
- Japanese pharmaceutical regulations
- International harmonization where applicable
- Continuous improvement programs
Production Capacity
Manufacturing Infrastructure:
- Dedicated manufacturing facility in Japan
- Capacity for commercial production
- Quality control laboratories
- Storage and distribution capabilities
Competitive Positioning
Market Opportunity
The addressable market for SB623 includes:
Traumatic Brain Injury:
- Significant patient population with chronic deficits
- Limited treatment options currently available
- High unmet medical need
Ischemic Stroke:
- Large patient population globally
- Significant burden of post-stroke disability
- No approved disease-modifying therapies
Strategic Advantages
SanBio's Position:
- First-mover in Japanese cell therapy for neurological conditions
- Proprietary technology platform
- Established safety and efficacy data
- Strong IP portfolio
- Experienced leadership team
Future Development Roadmap
Near-term Priorities
Commercial Launch: Execute successful AKUUGO launch in Japan
Stroke Development: Complete regulatory submissions for stroke indication
Manufacturing Scale: Ensure adequate supply for commercial needs
Clinical Data: Publish long-term follow-up dataMedium-term Goals
International Expansion: Pursue regulatory approvals in US and EU
Pipeline Development: Advance next-generation products
Combination Strategies: Explore combination therapy approaches
Indications Expansion: Evaluate additional neurological conditionsLong-term Vision
SanBio's long-term vision includes:
- Becoming a global leader in regenerative medicine for CNS disorders
- Expanding into additional therapeutic areas
- Developing innovative platforms beyond cell therapy
- Creating sustainable value for patients and shareholders
Research Publications
Key Publications
SanBio's research has been published in peer-reviewed journals:
Clinical Publications:
- Phase 1/2a TBI trial results
- Phase 2 stroke trial results
- Long-term follow-up data
Preclinical Publications:
- Mechanism of action studies
- Animal model efficacy
- Safety and toxicology
Conference Presentations
SanBio presents at major conferences:
- Society for Neuroscience
- American Academy of Neurology
- International Society for Stem Cell Research
- Japanese neurological conferences
See Also
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Traumatic Brain Injury](/diseases/traumatic-brain-injury)
- [Stroke](/diseases/stroke)
- [Mesenchymal Stem Cells](/cell-types/mesenchymal-stem-cells)
- [Regenerative Medicine](/therapeutics/regenerative-medicine)
- [Cell Therapy](/therapeutics/cell-therapy)
- [Japanese Pharmaceutical Companies](/companies/japanese-pharmaceutical)
- [Neurotrophic Factors](/mechanisms/neurotrophic-factors)
- [BDNF](/proteins/bdnf)
- [GDNF](/proteins/gdnf)
External Links
- [SanBio Official Website](https://www.sanbio.com/en/)
- [SanBio Company Overview](https://www.sanbio.com/en/)
- [SB623 Product Information](https://www.sanbio.com/en/)
- [AKUUGO Product Approval (2025)](https://www.sanbio.com/en/)
- [ClinicalTrials.gov - SB623 TBI](https://clinicaltrials.gov)
- [ClinicalTrials.gov - SB623 Stroke](https://clinicaltrials.gov)
- [PubMed - MSC Research](https://pubmed.ncbi.nlm.nih.gov/)
- [ScienceDirect - Regenerative Medicine](https://www.sciencedirect.com/)
- [ScienceDirect - Cell Therapy](https://www.sciencedirect.com/)
- [PubMed - TBI Research](https://pubmed.ncbi.nlm.nih.gov/)
- [PubMed - Stroke Research](https://pubmed.ncbi.nlm.nih.gov/)
- [PubMed - Neural Repair](https://pubmed.ncbi.nlm.nih.gov/)
- [PMDA - Japanese Regulations](https://www.pmda.go.jp/)
- [Tokyo Stock Exchange](https://www.jpx.co.jp/)
- [Japan Biotechnology Association](https://www.jba.or.jp/)
- [Japanese Regenerative Medicine Society](https://www.jsrm.jp/)
- [Nature - Stem Cell Research](https://www.nature.com/)
References
[SanBio Official Website](https://www.sanbio.com/en/)
[SanBio Company Overview](https://www.sanbio.com/en/)
[SB623 Product Information](https://www.sanbio.com/en/)
[AKUUGO Product Approval (2025)](https://www.sanbio.com/en/)
[ClinicalTrials.gov - SB623 TBI](https://clinicaltrials.gov)
[ClinicalTrials.gov - SB623 Stroke](https://clinicaltrials.gov)
[PubMed - Mesenchymal Stem Cells Research](https://pubmed.ncbi.nlm.nih.gov/)
[ScienceDirect - Regenerative Medicine for CNS](https://www.sciencedirect.com/)
[ScienceDirect - Cell Therapy for Neurological Disorders](https://www.sciencedirect.com/)
[PubMed - Traumatic Brain Injury Treatment](https://pubmed.ncbi.nlm.nih.gov/)
[PubMed - Stroke Rehabilitation](https://pubmed.ncbi.nlm.nih.gov/)
[PubMed - Neural Repair Mechanisms](https://pubmed.ncbi.nlm.nih.gov/)
[PubMed - Nogo Receptor and Neural Regeneration](https://pubmed.ncbi.nlm.nih.gov/)
[PubMed - Glial Cell Line-Derived Neurotrophic Factor](https://pubmed.ncbi.nlm.nih.gov/)
[PubMed - Brain-Derived Neurotrophic Factor](https://pubmed.ncbi.nlm.nih.gov/)
[PubMed - Neuroinflammation in CNS Repair](https://pubmed.ncbi.nlm.nih.gov/)
[ClinicalTrials.gov - Clinical Cell Therapy Trials](https://clinicaltrials.gov)
[PMDA - Japanese Regenerative Medicine Regulations](https://www.pmda.go.jp/)
[Tokyo Stock Exchange - SanBio](https://www.jpx.co.jp/)
[Japanese Biotechnology Companies](https://www.jba.or.jp/)
[Regenerative Medicine Promotion Society Japan](https://www.jsrm.jp/)
[Nature - Stem Cell Research](https://www.nature.com/)